Oxford Vacmedix (OVM), a UK-based biopharmaceutical spinout from University of Oxford, today closed a £9m ($12.5m) series A round featuring molecular diagnostics company Cancer ROP.
The round also featured unnamed, existing shareholders based in China.
Founded in 2012, Oxford Vacmedix has created a platform to develop cancer vaccines and diagnostic tools. The approach exploits recombinant overlapping peptides (ROP), which stimulate T cell immunity – T cells are a natural part of the human system and an important basis for immunotherapy.
…
